1 / 20

B Cells and blood stage malaria

B Cells and blood stage malaria. Sean Elias. Malaria Life Cycle. Antigen Constructs. FVO Ectodomain. tPA. 3D7. FVO Terminus. F VO-33 FVO-19. MSP-1. MSP-1: Merozoite surface protein. 19 fragment contains major B cell epitopes (anchored to RBCs during invasion)

loe
Download Presentation

B Cells and blood stage malaria

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. B Cells and blood stage malaria Sean Elias

  2. Malaria Life Cycle

  3. Antigen Constructs FVO Ectodomain tPA 3D7 FVO Terminus F VO-33 FVO-19 MSP-1 • MSP-1: Merozoite surface protein. • 19 fragment contains major B cell epitopes (anchored to RBCs during invasion) • Preclinical association of 19 antibodies with protection • 33 fragment contains Th cell epitopes • AMA-1: Apical membrane antigen. • Required for RBC invasion • Preclinical association of antibodies with protection 1 3 5 12 3D7-33 3D7-19 Glycine-Proline linker Glycine-Proline linker AMA-1

  4. Clinical Trial Structure VAC36 VAC37 8wk Adeno Prime MVA Boost

  5. Clinical Trial Structure VAC39

  6. Vac1 AdCh63 Vac1 AdCh63 Vac1 AdCh63 = Blood test AdCh63 = AdCh63 AMA-1 (VAC36), MSP-1 (VAC37) • MVA = MVA AMA1 (VAC36), MSP-1 (VAC37) S = Screening S S S D0 D2 D28 D56 D14 D0 D63 D84 D90 D28 D2 D14 D14 D28 D56 D58 D140 D2 D0 D63 C-1 D56 D58 C+21 / DoD Vac 2 MVA Vac 2 MVA Volunteer Bleeds C+7 C+11 C+35 C+90

  7. Memory B Cells and Malaria • What is the effect of challenge/infection on mBC expansion? • The P. falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections. Weiss 2010 • Long-lived antibody and B cell memory to P. falciparumin low transmission areas. Wipasa 2010 • P. YoeliiCan Ablate Vaccine-Induced Long Term protection in mice. Wykes 2005 • Kenyan children exposed to malaria may develop antibody but not memory to blood stage antigens (AMA-1 more so than MSP-1) Dorfman 2005 • Decreases in memory and naive B cell subsets in Kenyan children with acute P. falciparum infection. Asito 2008 • Atypical memory B cells (‘exhausted’) are greatly expanded in individuals living in a malaria-endemic area. Weiss 2009 • A Positive Correlation between Atypical Memory B Cells and Plasmodium falciparum Transmission Intensity in Cross-Sectional Studies in Peru and Mali Weiss 2011

  8. VAC37 : MSP-1 Antibody Data A B Group 1A Group 1B C D Group 2A Group 2B+2C ELISA DATA: S. Draper

  9. VAC37 : MSP-1 Memory B Cell ELIspot Challenge Boost Boost Prime Prime Day of Diagnosis

  10. VAC37 : MSP-1 Memory B Cell ELIspot

  11. VAC37 : MSP-1 Memory B Cell ELIspot • Boost required for significant B cell response • mBC’s correlate with Ab’s

  12. VAC36 : AMA-1 Memory B Cell ELIspot P= 0.0962 ELISA DATA: S. Draper, S. Biswas

  13. VAC39 Controls • 3/5 controls had mBC response to MSP-1 at 35 days after challenge • No response to AMA-1 • Appears to be rough correlation with Ab titre for MSP-1. Needs more power to confirm relationship. • Only 2/5 volunteers showed low Ab titre to AMA-1 at C+35 • Kenyan children exposed to malaria may develop antibody but not memory to blood stage antigens (AMA-1 more so than MSP-1) Dorfman 2005

  14. Memory B Cell ELIspots • Conclusions: • Ad/MVA prime boost regime induces mBC formation to both MSP-1 & AMA-1 • Following this regime with parasite exposure further boosts mBCs to levels much higher than seen through natural exposure (up to x10?) • mBC derived B cells appear to correlate with Ab titre • Activation of mBC by malaria antigens does not appear to activate other mBC’s (Diphtheria) by bystander effect • Blood stage parasitemia appears to deplete circulating mBC’s but this doesn’t effect boosting when patients drug cured at cut-off peak parasitemia. • Will be interesting to see boost effect of challenge on vaccinees on AMA-1 given lack of seroconversion and mBC’s in controls. • VAC39 aims: • Replicate data for challenged volunteers (Group 1) • Look for effect of challenge on mBC’s for AMA-1 (Group 2) • Study effect of dual antigen vaccination on mBC formation (Group 3)

  15. VAC39 : ASC ELIspot • Ahmed 2008: Showed that for flu vaccination there was a rapid and robust influenza specific IgG+ antibody secreting plasma cell (ASC) response that peaked at approximately day 7 after boosting. • Questions: • What time after boosting can we see a peak? Limited to D63 with current protocol. • What % of cells detected are antigen specific. • When during challenge can such cells be seen? • Is there a correlation with Antibody production?

  16. VAC39 : ASC ELIspot

  17. VAC39 : ASC ELIspot • Answers?: • Peak likely to be somewhere between day 5 and 8. • Harder to calculate total IgG secreting cells compared to mBC assay. • No ASC’s detected during challenge (C+7, C+11) • No ASC’s detected in protected volunteer at C+21 • No significant correlation with Antibody production Day 63.

  18. VAC44 : Upcoming Trial

  19. VAC44 : Experimental Plan • ASC ELIspots: • Additional timepoints for detection (1, 4 & 7 days post boost) • More regulation on visit windows so these time points more accurate • Can test whether successive boosts shorten time for peak response • Can compare effect of boost regimes. Vectors/Protein/Adjuvant. • mBCELIspots: • Can compare effect of boost regimes. Vectors/Protein. • Effect of CPG adjuvant (mBC stimulator)

  20. Future Work • B cell phenotyping • Atypical memory B cells (‘exhausted’): Are they induced in our vaccination regimes or during controlled challenge? • B cell clonality • Clonal dissection of mBC repertoire (Pinna 2009). • Clonal burst size • Antibody production on clonal level • B cell receptor (BCR) variable region genes will be cloned and sequenced to assess the antibody / BCR repertoire induced by different priming and boosting vaccinations • Does successive vaccinations/challenge give a more directed, higher affinity response?

More Related